Why the study?
Does cholecalciferol reduce systemic RAS activity in drug-free patients with essential hypertension and hypovitaminosis D?
Population
15 consecutive drug-free patients with essential hypertension and hypovitaminosis D
Design
Cohort
Follow-up
two months
Authors
Loading...
Supports vitamin D repletion to blunt RAS activity in deficient hypertensives; leaves open BP effects and needs randomized confirmation.
Does cholecalciferol reduce systemic RAS activity in drug-free patients with essential hypertension and hypovitaminosis D?
Pharmacological correction of vitamin D levels with cholecalciferol blunts systemic RAS activity in essential hypertensives with hypovitaminosis D, though it did not lower blood pressure in this small study.
Carrara et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: